Alipay Supports Xi’an to Build “International Consumer Friendly Tourist Destination”
Alipay, the leading digital payment and lifestyle service platform, today announced that it is working with Xi’an, the world-renowned ancient capital city located in Shaanxi province famous for the Terracotta Warriors, to launch the “International Consumer Friendly Tourist Destination” initiative. With the resurgence of inbound tourism to China, the initiative aims to enhance the travel and shopping experiences of international visitors to Xi’an and boost the city’s tourism industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524320945/en/
Launch ceremony of “International Consumer Friendly Tourist Destination” Xi’an (Photo: Business Wire)
Alipay – with the support and guidance of local authorities – is working with its partners in Xi’an, including tourist attractions, hotels, restaurants, and public transit agencies, to upgrade their payment and digital services for international travelers.
International visitors can now link their international Visa, Mastercard, JCB, Discover®, or Diners Club International® credit or debit card in the Alipay app to easily pay at a wide range of Chinese mainland merchants in the Alipay merchant network.
In addition to paying like a local with Alipay, international tourists can also use their home e-wallet while exploring China. These e-wallets include AlipayHK (Hong Kong SAR, China), MPay (Macao SAR, China), Touch ’n Go eWallet (Malaysia) and Kakao Pay (South Korea), Hipay (Mongolia), Changi Pay (Singapore), OCBC (Singapore), Naver Pay (South Korea), Toss Pay (South Korea), TrueMoney (Thailand), NayaPay (Pakistan), and Kaspi.kz (Kazakhstan).
Following the successful introduction of digital red packets, which international tourists could claim by scanning a QR code at Mount Huangshan before the May Day holiday in 2024, Alipay is expanding the service. Effective immediately through June 30, international travelers in Xi’an can claim digital red packets for discounts on offline purchases throughout China. Participating merchants include tourist attractions such as Tang Paradise and the Longest Day in Chang'an Theme Block, Lanxiangzi and other chain restaurants, Chahuanong and other tea brands, and food streets like Yongxing Fang, as well as metro and bus stations.
According to Alipay statistics, the transaction volume of international visitors using Alipay in Xi’an has increased by nearly seven times in the first four months of 2024, compared to the same period last year. The data showed that the top ten tourist attractions that international visitors pay through Alipay are: the Great Tang All Day Mall, Tang Paradise, Emperor Qinshihuang's Mausoleum Site Museum, Mount Huashan, Bell and Drum Tower, Daming Palace National Heritage Park, Huaqing Palace, Tang West Market Museum, Yongxing Fang, and the Hancheng Lake Scenic Area.
Alipay provides global tourists with a convenient and secure mobile payment service and various travel services to enhance their travel experience in China through collaboration with industry partners. Accessible directly from Alipay's homepage, these easy-to-access services include online translation, ride-hailing services, public transport, hotel reservations, and train ticket bookings.
“Alipay looks forward to working with even more partners to enhance the payment and travel experience for both domestic and international tourists. We aim to support an increasing amount of local tourist attractions and commercial districts to create a travel and shopping experience that is welcoming to visitors from all around the world,” said Jiajia Li, vice president of Alipay business group at Ant Group.
About Alipay
In the digital era, Alipay has evolved from a trusted payment tool to an open platform that connects businesses, institutions, service providers, and other partners with consumers. Alipay enables partners from various industries to offer safe and convenient payment options. It also enables partners to communicate and deliver different digital services to their customers in China through Alipay mini programs, lifestyle accounts and other tools. The Alipay platform has connected over 80 million businesses with more than one billion consumers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240524320945/en/
Contact information
Media Inquiries
Bell Wang
yixing.wl@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom